Hamostaseologie最新文献

筛选
英文 中文
Epidemiology, Health Care Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Analysis of German Claims Data from 2016 to 2021. 血友病A和B治疗方案的流行病学、卫生保健资源利用和成本:2016年至2021年德国索赔数据的回顾性分析
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-07-14 DOI: 10.1055/a-2558-9886
Dominik Obermüller, Karin Berger, Robert Klamroth, Maria Kleppisch, Stephan Rauchensteiner, Ines Ecke, Sandra Hermann, Dorota Pawlowska-Phelan, Dennis Häckl, Agnes Kisser
{"title":"Epidemiology, Health Care Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Analysis of German Claims Data from 2016 to 2021.","authors":"Dominik Obermüller, Karin Berger, Robert Klamroth, Maria Kleppisch, Stephan Rauchensteiner, Ines Ecke, Sandra Hermann, Dorota Pawlowska-Phelan, Dennis Häckl, Agnes Kisser","doi":"10.1055/a-2558-9886","DOIUrl":"https://doi.org/10.1055/a-2558-9886","url":null,"abstract":"<p><p>In Germany, hemophilia patients with a severe bleeding phenotype receive lifelong prophylactic treatment with intravenous concentrated factor VIII (FVIII) or IX (FIX) to prevent bleeding events. To assess the economic value of emerging treatment options, studies describing the economic burden of hemophilia under the current standard of care in Germany are needed.This study classified hemophilia A (HA) and B (HB) patients by treatment regimen in administrative claims data to examine the real-world economic burden of Hemophilia in Germany from 2016 to 2021.Hemophilia patients were identified in InGef statutory health insurance claims data via ICD-10 codes D66 (HA) and D67 (HB) in combination with one or more claims for hemophilia-related medication.Each patient's factor regimen was classified as either indicative of a severe phenotype needing prophylaxis or a non-severe phenotype treated on demand using a classification threshold of 100,000 International Units (IU) FVIII/year (HA) and 80,000 IU FIX/year (HB). Health care resource utilization and cost outcomes were captured for each study year.Male prevalence per 100,000 ranged from 6.39 to 7.81 (HA) and 1.26 to 1.89 (HB), with 43 to 53% (HA) and 40 to 56% (HB) categorized as severe. In 2021, mean (standard deviation [SD]) per-patient medication costs were €321,987 (€157,915) in the severe treatment group versus €43,487 (€92,821) in the non-severe group for HA and €289,411 (€132,400) versus €19,253 (€23,655) for HB.The results demonstrate the high economic burden of severe HA and HB in Germany, driven by the need for continuous factor replacement therapy, and give an estimate of treatment costs based on a real-world therapy mix.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Platelet microRNAs in Cancer. 血小板微rna在癌症中的作用。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-07-14 DOI: 10.1055/a-2617-9786
I A Dremuk, A N Sveshnikova, E V Shamova
{"title":"The Role of Platelet microRNAs in Cancer.","authors":"I A Dremuk, A N Sveshnikova, E V Shamova","doi":"10.1055/a-2617-9786","DOIUrl":"https://doi.org/10.1055/a-2617-9786","url":null,"abstract":"<p><p>There is strong evidence that platelets significantly contribute to cancer progression. Numerous studies have shown that microRNAs in platelet microvesicles play an important role in different stages of cancer and can serve as new diagnostic and prognostic biomarkers. Since platelet microRNAs have opposing purposes, it is challenging to make clear-cut judgements regarding their involvement in carcinogenesis. However, it is well known that the processes regulated by microRNAs in cancer include cell proliferation, cell death, epithelial-mesenchymal transition, cancer metastasis, and angiogenesis. This review focusses on and summarizes current research in the field of platelet-cancer interactions and discusses the role of platelet microRNAs in cancer development, which is a promising area for future research and therapeutic development.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Genetic and Acquired Risk Factors on Thromboembolic Events: A Retrospective Study. 遗传和后天危险因素对血栓栓塞事件的影响:一项回顾性研究。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-07-08 DOI: 10.1055/a-2614-8526
Luca Rapino, Ana-Luisa Stefanski, Thomas Dörner
{"title":"The Impact of Genetic and Acquired Risk Factors on Thromboembolic Events: A Retrospective Study.","authors":"Luca Rapino, Ana-Luisa Stefanski, Thomas Dörner","doi":"10.1055/a-2614-8526","DOIUrl":"https://doi.org/10.1055/a-2614-8526","url":null,"abstract":"<p><p>This study, involving a cohort of 980 patients with arterial and/or venous events, evaluated the relative importance of genetic and traditional risk factors using a machine learning model approach. The analysis revealed that conventional risk factors-such as age, gender, tobacco use, obesity-and acquired thrombophilia (most prominently antiphospholipid syndrome [APS]) outperformed any genetic risk variants analyzed. Of note, the presence of heterozygous FVL mutations was associated with a reduced arterial risk, whereas carriers of heterozygous factor VII activation protease (FSAP) mutations had a lower risk of venous events.Thus, by employing diverse statistical approaches, the study showed that acquired risk factors exert the most substantial impact on the development of thrombotic events, except for the well-known role of FVL mutations in venous events.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary Combined Deficiency of the Vitamin K-Dependent Coagulation Factors. 维生素k依赖性凝血因子的遗传性联合缺乏。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-04 DOI: 10.1055/a-2567-3567
Alexandre Raharimanana, Séverine Cunat, Céline Falaise, Caroline Oudot, Alexandra Fournel, Yesim Dargaud
{"title":"Hereditary Combined Deficiency of the Vitamin K-Dependent Coagulation Factors.","authors":"Alexandre Raharimanana, Séverine Cunat, Céline Falaise, Caroline Oudot, Alexandra Fournel, Yesim Dargaud","doi":"10.1055/a-2567-3567","DOIUrl":"10.1055/a-2567-3567","url":null,"abstract":"<p><p>Hereditary combined vitamin K-dependent coagulation factor deficiency (VKCFD) is an extremely rare autosomal recessive genetic disorder characterized by deficiencies in vitamin K-dependent coagulation factors and natural anticoagulants. The condition presents with a spectrum of bleeding symptoms ranging from mild to severe, often beginning in the neonatal period. These bleeding episodes can be particularly severe and even life-threatening, occurring spontaneously or during surgery. In addition to bleeding problems, individuals with VKCFD may experience a variety of non-hemostatic problems, including skeletal deformities, cardiovascular abnormalities, and skin conditions.VKCFD is caused by variants in the genes encoding either γ-glutamyl carboxylase or the vitamin K 2,3-epoxide reductase complex. Both proteins play a critical role in γ-carboxylation, a posttranslational modification that is essential for the proper function of vitamin K-dependent proteins. Timely and accurate diagnosis is essential to differentiate VKCFD from other genetic and acquired disorders, and genetic testing is required to identify the specific variant.The primary treatment for VKCFD is the administration of vitamin K, with transfusions of fresh frozen plasma often required during surgery or in cases of severe bleeding. In certain situations, alternative therapies such as prothrombin complex concentrates (PCCs) or a combination of recombinant activated factor VII and vitamin K may be considered. With appropriate treatment, individuals with VKCFD generally have a good clinical outcome, and the condition has a limited impact on their quality of life. This article presents a comprehensive review of all 57 VKCFD cases documented in the literature, as well as 4 new, unpublished cases from France.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnostic Assessment of Inherited Platelet Function Defects - Part 1: An Overview of the Diagnostic Approach and Laboratory Methods. 遗传性血小板功能缺陷的诊断评估。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2025-01-27 DOI: 10.1055/a-2436-5318
Gero Hoepner, Karina Althaus, Jens Müller, Barbara Zieger, Anna Pavlova, Doris Boeckelmann, Ralf Knöfler, Peter Bugert, Beate Kehrel, Werner Streif, Ingvild Birschmann, Heiko Rühl, Ulrich Sachs, Florian Prüller, Carlo Zaninetti, Harald Schulze, Nina Cooper, Kerstin Jurk, Tamam Bakchoul
{"title":"The Diagnostic Assessment of Inherited Platelet Function Defects - Part 1: An Overview of the Diagnostic Approach and Laboratory Methods.","authors":"Gero Hoepner, Karina Althaus, Jens Müller, Barbara Zieger, Anna Pavlova, Doris Boeckelmann, Ralf Knöfler, Peter Bugert, Beate Kehrel, Werner Streif, Ingvild Birschmann, Heiko Rühl, Ulrich Sachs, Florian Prüller, Carlo Zaninetti, Harald Schulze, Nina Cooper, Kerstin Jurk, Tamam Bakchoul","doi":"10.1055/a-2436-5318","DOIUrl":"10.1055/a-2436-5318","url":null,"abstract":"<p><p>In this article, our goal is to offer an introduction and overview of the diagnostic approach to inherited platelet function defects (iPFDs) for clinicians and laboratory personnel who are beginning to engage in the field. We describe the most commonly used laboratory methods and propose a diagnostic four-step approach, wherein each stage requires a higher level of expertise and more specialized methods. It should be noted that our proposed approach differs from the ISTH Guidance on this topic in some points. The first step in the diagnostic approach of iPFD should be a thorough medical history and clinical examination. We strongly advocate for the use of a validated bleeding score like the ISTH-BAT (International Society on Thrombosis and Haemostasis Bleeding Assessment Tool). External factors like diet and medication have to be considered. The second step should rule out plasmatic bleeding disorders and von Willebrand disease. Once this has been accomplished, the third step consists of a thorough platelet investigation of platelet phenotype and function. Established methods consist of blood smear analysis by light microscopy, light transmission aggregometry, and flow cytometry. Additional techniques such as lumiaggregometry, immune fluorescence microscopy, and platelet-dependent thrombin generation help confirm and specify the diagnosis of iPFD. In the fourth and last step, genetic testing can confirm a diagnosis, reveal novel mutations, and allow to compare unclear genetics with lab results. If diagnosis cannot be established through this process, experimental methods such as electron microscopy can give insight into the underlying disease.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"229-242"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blutungsrisiko bei NSAIR unter Antikoagulanzien. 抗凝剂下的非甾体抗炎药出血风险。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2025-06-23 DOI: 10.1055/s-0045-1809871
{"title":"Blutungsrisiko bei NSAIR unter Antikoagulanzien.","authors":"","doi":"10.1055/s-0045-1809871","DOIUrl":"https://doi.org/10.1055/s-0045-1809871","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 3","pages":"227"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria. 一名阵发性夜间血红蛋白尿患者的多处血栓形成。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2024-02-09 DOI: 10.1055/a-2231-5277
Lennart Beckmann, Tobias D Faizy, Fabian Flottmann, Jens Fiehler, Carsten Bokemeyer, Lennart Well, Antonia Beitzen-Heineke, Florian Langer
{"title":"Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria.","authors":"Lennart Beckmann, Tobias D Faizy, Fabian Flottmann, Jens Fiehler, Carsten Bokemeyer, Lennart Well, Antonia Beitzen-Heineke, Florian Langer","doi":"10.1055/a-2231-5277","DOIUrl":"10.1055/a-2231-5277","url":null,"abstract":"<p><strong>Case: </strong>Paroxysmal nocturnal hemoglobinuria (PNH) is an extremely rare bone marrow disorder caused by acquired mutations in the phosphatidylinositol glycan class A gene, which lead to a partial or total loss of the cellular complement regulators CD55 and CD59.1 In addition to complement-mediated hemolysis and cytopenia, venous and arterial thromboses at multiple and/or unusual sites are a common complication and occur in up to 44% of patients in historic PNH cohorts.1 2.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"262-265"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. Informiert. 血栓和止血研究协会。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2025-06-23 DOI: 10.1055/a-2568-4247
{"title":"Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. Informiert.","authors":"","doi":"10.1055/a-2568-4247","DOIUrl":"https://doi.org/10.1055/a-2568-4247","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"45 3","pages":"266-268"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnostic Assessment of Platelet Function Defects - Part 2: Update on Platelet Disorders. 血小板功能缺陷的诊断评估。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2025-01-27 DOI: 10.1055/a-2404-0216
Karina Althaus, Gero Hoepner, Barbara Zieger, Florian Prüller, Anna Pavlova, Doris Boeckelmann, Ingvild Birschmann, Jens Müller, Heiko Rühl, Ulrich Sachs, Beate Kehrel, Werner Streif, Peter Bugert, Carlo Zaninetti, Nina Cooper, Harald Schulze, Ralf Knöfler, Tamam Bakchoul, Kerstin Jurk
{"title":"The Diagnostic Assessment of Platelet Function Defects - Part 2: Update on Platelet Disorders.","authors":"Karina Althaus, Gero Hoepner, Barbara Zieger, Florian Prüller, Anna Pavlova, Doris Boeckelmann, Ingvild Birschmann, Jens Müller, Heiko Rühl, Ulrich Sachs, Beate Kehrel, Werner Streif, Peter Bugert, Carlo Zaninetti, Nina Cooper, Harald Schulze, Ralf Knöfler, Tamam Bakchoul, Kerstin Jurk","doi":"10.1055/a-2404-0216","DOIUrl":"10.1055/a-2404-0216","url":null,"abstract":"<p><p>Congenital platelet disorders are rare and targeted treatment is usually not possible. Inherited platelet function disorders (iPFDs) can affect surface receptors and multiple platelet responses such as defects of platelet granules, signal transduction, and procoagulant activity. If iPFDs are also associated with a reduced platelet count (thrombocytopenia), it is not uncommon to be misdiagnosed as immune thrombocytopenia. Because the bleeding tendency of the different platelet disorders is variable, a correct diagnosis of the platelet defect based on phenotyping, function analysis, and genotyping is essential, especially in the perioperative setting. In the case of a platelet receptor deficiency, such as Bernard-Soulier syndrome or Glanzmann thrombasthenia, not only the bleeding tendency but also the risk of isoimmunization after platelet transfusions or pregnancy has to be considered. Platelet granule disorders are commonly associated with either intrinsically quantitative or qualitative granule defects due to impaired granulopoiesis, or granule release defects, which can also affect additional signaling pathways. Functional platelet defects require expertise in the clinical bleeding tendency in terms of the disorder when using antiplatelet agents or other medications that affect platelet function. Platelet defects associated with hematological-oncological diseases require comprehensive information about the patient including the clinical implication of the genetic testing. This review focuses on genetics, clinical presentation, and laboratory platelet function analysis of iPFDs with or without reduced platelet number. As platelet defects affecting the cytoskeleton usually show thrombocytopenia, but less impaired or normal platelet functional responses, they are not specifically addressed.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"243-253"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Anticoagulation and Mortality in Cases with Intracranial Bleeding: Analysis of Nationwide Prescription and Hospitalization Data. 口服抗凝药与颅内出血病例的死亡率:全国处方和住院数据分析》。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2025-06-01 Epub Date: 2024-02-05 DOI: 10.1055/a-2229-8047
Knut Kröger, Fabian Heldt, Ludger Feyen, Kathrin Feller, Bernd Kowall, Andreas Stang
{"title":"Oral Anticoagulation and Mortality in Cases with Intracranial Bleeding: Analysis of Nationwide Prescription and Hospitalization Data.","authors":"Knut Kröger, Fabian Heldt, Ludger Feyen, Kathrin Feller, Bernd Kowall, Andreas Stang","doi":"10.1055/a-2229-8047","DOIUrl":"10.1055/a-2229-8047","url":null,"abstract":"<p><strong>Objectives: </strong> To demonstrate the safety of direct oral anticoagulants in relation to intracranial bleeding (ICB), we compared the number of patients taking anticoagulants in all cases of hospitalization and cases of hospitalization for ICB over time in Germany. We analyzed the intrahospital mortality of ICB cases in relation to long-term use of anticoagulants (LUAs).We performed a retrospective registry analysis of nationwide German hospitalizations including all hospital admissions and admission for ICB in patients aged ≥60 years in the period from 2006 to 2020 and separated for LUAs.</p><p><strong>Results: </strong> In 2006, the age-standardized rate of hospitalized male patients with LUAs was 7.3% and that of female patients was 5.6%. In 2020, the rates increased to 22.0 and 17.7% for male and female patients, respectively. Among patients hospitalized for ICB in 2006, 7.0 and 5.6% were male and female patients with LUAs, respectively. In 2020, the rate increased to 13.7% for males and 10.8% for females.In 2006, age-standardized mortality rates of male and female patients with ICB without LUAs were 24.1 and 23.9%, respectively. In 2020, the rate slightly decreased to 22.7% in males, but it remained almost unchanged in females at 23.8%. In the cases with LUA, the mortality rate decreased from 30.1 to 24.3% in males and from 28.4 to 24.2% in females in the same period.</p><p><strong>Conclusion: </strong> LUA seems to be safe because there is a slower increase of the rate of LUAs in ICB cases than in generally hospitalized cases in the period from 2006 to 2020. In addition, mortality in ICB cases with LUA tends to decrease compared to cases without LUA.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"254-261"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信